Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "NAFLD"

13 News Found

‘SMART’ program for Ayurveda professionals to boost research in Ayurveda
Policy | January 03, 2023

‘SMART’ program for Ayurveda professionals to boost research in Ayurveda

The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research

SRL Diagnostics launches fatty liver index
Clinical Trials | July 13, 2022

SRL Diagnostics launches fatty liver index

An algorithm based testing for Fatty Liver Disease

Zydus announces update on a randomised trial of Saroglitazar Mg in NASH
Biotech | October 22, 2021

Zydus announces update on a randomised trial of Saroglitazar Mg in NASH

Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders

Latest Stories

Lupin receives positive CHMP opinion for biosimilar Ranibizumab

Biocon Biologics honored as 2025 Asia IP Elite by IAM for 9th consecutive year

AstraZeneca India receives permission from CDSCO for Datopotamab Deruxtecan powder

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging